NEW YORK (GenomeWeb) – Canadian molecular diagnostics company Proteocyte Diagnostics today said that it closed a funding round that raised C$605,000 (US$554,000).

Investors included the Ontario Centres of Excellence, which provided C$250,000 in the financing, as well as a private syndicate of investors. The proceeds will be used to drive commercialization of Proteocyte's Straticyte diagnostic test for oral cancers, the Toronto-based company said. Proteocyte, which was founded in 2011, said on its website that it anticipates launching the test in 18 to 24 months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.